<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed the outcome in 22 children with refractory or relapsed non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who underwent autologous peripheral blood progenitor cell transplantation between 1994 and 2009 </plain></SENT>
<SENT sid="1" pm="."><plain>The conditioning regimen used in <z:hpo ids='HP_0000001'>all</z:hpo> patients consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Median age was 6 years (range 2 to 16 y) </plain></SENT>
<SENT sid="3" pm="."><plain>The most common histologic subtype was Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Ten patients were in complete remission and 12 in partial remission at the time of transplant </plain></SENT>
<SENT sid="5" pm="."><plain>The median dose of CD34+ cells that was infused was 4.6 × 10/kg (range 2.1 to 58.7 × 10/kg) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients were engrafted, with a median time for neutrophils and platelets recovery of 11 (range, 8 to 15 d) and 14 (range, 9 to 60 d) days, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Nonhematologic treatment-related toxicity included severe mucositis in 3 patients and hepatic <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> in 1 patient </plain></SENT>
<SENT sid="8" pm="."><plain>There were no transplant-related mortalities </plain></SENT>
<SENT sid="9" pm="."><plain>With a median follow-up of 60 months (range, 4 to 180 d) the disease-free survival was 90 ± 6.5% for the whole group </plain></SENT>
<SENT sid="10" pm="."><plain>This retrospective study shows a high long-term survival using <z:chebi fb="0" ids="28901">busulfan</z:chebi>/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> as conditioning regimen in children with refractory or relapsed non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>